Media Room
Sanofi’s breakthrough therapy Rezurock® approved in India for treating patients living with chronic graft-versus-host disease (cGVHD)
Announcement February 10, 2025
Sanofi Healthcare India Pvt. Limited announces receipt of marketing authorization for Rezurock® (Belumosudil Tablets) in India.
Sanofi receives marketing authorization for Beyfortus® in India to protect infants & children against Respiratory Syncytial Virus (RSV)
Announcement July 31, 2024
Sanofi (India) announced that on 10th June 2024 it has received marketing authorization approval from the Central Drugs Standard Control Organization (CDSCO) for Beyfortus in India.
Sanofi’s diabetes drug Soliqua® now available in India
Announcement April 25, 2024
Sanofi India Limited has launched its’ new diabetes drug Soliqua® after having received the marketing authorization from the Central Drugs Standard Control Organization (CDSCO) earlier last year.
